XUNFEIHEALTH (02506) announced its annual performance, with operating income reaching 915 million yuan, a year-on-year increase of 24.7%.
Xunfei Medical Technology (02506) announced its annual performance for the year ending December 31, 2025, with revenue of 915 million RMB, an increase of 24.7% year-on-year; net loss attributable to the parent company of 64.788 million RMB, a decrease of 51.1% year-on-year; and gross profit of 462 million RMB, an increase of 14.2% year-on-year.
XUNFEIHEALTH (02506) announced its annual performance as of December 31, 2025, with revenue of RMB 915 million, a year-on-year increase of 24.7%; a net loss attributable to owners of the company of RMB 64.788 million, a year-on-year decrease of 51.1%; and a gross profit of RMB 462 million, a year-on-year increase of 14.2%.
In 2025, the company actively expanded its market and continued to increase its customer base. As of December 31, 2025, the company provided products and services to more than 77,000 grassroots medical institutions, covering 806 counties in 31 provinces, as well as over 600 hospitals. The extensive market coverage fully demonstrates the company's technological leadership, market competitiveness, and the efficiency of its marketing system, laying a solid foundation for the company's rapid business development.
With its leading technological capabilities, extensive customer base, and brand recognition, the company continuously improves its operational efficiency and seizes new profit opportunities through synergistic commercialization strategies. As of December 31, 2025, the company recorded a revenue increase of 24.7%, a gross profit increase of 14.2%, and a gross profit margin of 50.5%, maintaining at a reasonably high level. With the enrichment and maturity of the company's products, the company expects rapid growth in revenue scale, while the comprehensive gross profit margin level remains relatively stable.
The company closely revolves around the mission of becoming "the AI diagnostic assistant for every doctor and the AI health assistant for every person," leveraging industry-leading artificial intelligence technology and deep industry insights. The company has created a range of AI diagnostic assistant products and AI health assistant products, with business categories including "grassroots solutions, regional solutions, hospital solutions, and patient management services".
Related Articles

DL Holdings GP (01709) spent HK$1.836 million to repurchase 1.416 million shares on March 27th.

ZHONGCHANG INTL (00859) released its annual performance with a net loss attributable to shareholders of HK$201 million, an increase of 13.69% compared to the previous year.

CHINA HONGBAO (08316) signs debt waiver agreement with executive director Cheng Jun
DL Holdings GP (01709) spent HK$1.836 million to repurchase 1.416 million shares on March 27th.

ZHONGCHANG INTL (00859) released its annual performance with a net loss attributable to shareholders of HK$201 million, an increase of 13.69% compared to the previous year.

CHINA HONGBAO (08316) signs debt waiver agreement with executive director Cheng Jun

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


